Showing 3291-3300 of 21432 results for "".
- Laughter Exercise Could Be an Initial Treatment for Relieving Dry Eye Disease Symptomshttps://reachmd.com/news/laughter-exercise-could-be-an-initial-treatment-for-relieving-dry-eye-disease-symptoms/2468168/Laughter may be as effective as eye drops in improving symptoms of dry eye disease, finds a clinical trial from China published by The BMJ today. The researchers suggest that laughter exercise could be an initial treatment for rel
- E-Scooter Injuries on the Rise in Denver, Says CU School of Medicine Researchhttps://reachmd.com/news/e-scooter-injuries-on-the-rise-in-denver-says-cu-school-of-medicine-research/2468147/Want to avoid an injury from riding an electric scooter? Riders need to think twice about riding at night and jumping on after having a drink. Those are two of the takeaways from a new research study on electric scooter injuries conducted by
- University of Minnesota Scientists Discover Dual Roles of Antibodies in COVID-19 Infectionshttps://reachmd.com/news/university-of-minnesota-scientists-discover-dual-roles-of-antibodies-in-covid-19-infections/2468146/MINNEAPOLIS/ST. PAUL (09/10/2024) - Scientists at the University of Minnesota and the Midwest Antiviral Drug Discovery (AViDD) Center have made a surprising discovery: antibodies can have opposite effects on viral infections in
- Games, Puzzles, and Reading Can Slow Cognitive Decline in the Elderly — Even in Those with Mild Cognitive Impairmenthttps://reachmd.com/news/games-puzzles-and-reading-can-slow-cognitive-decline-in-the-elderly-even-in-those-with-mild-cognitive-impairment/2468149/The high-level participation group consistently exhibited higher cognitive function levels during the study period.Getty Images The aging process can lead to diminished cognitive functio
- How the Brain's Inner Chamber Governs Our State of Consciousnesshttps://reachmd.com/news/how-the-brains-inner-chamber-governs-our-state-of-consciousness/2468135/Schematic illustration of the primary conclusion. Credit: Nature Communications (2024). DOI: 10.1038/s41467-024-51837-1
- FDA Issues 'Letter of Support' Encouraging Use of Synuclein-based Biomarker, αSyn-SAA, in Clinical Trials in Parkinson's and Related Diseaseshttps://reachmd.com/news/fda-issues-letter-of-support-encouraging-use-of-synuclein-based-biomarker-syn-saa-in-clinical-trials-in-parkinsons-and-related-diseases/2468121/U.S. regulatory agency recognizes potential of alpha-synuclein seed amplification assay (αSyn-SAA) to accelerate clear outcomes in drugmakers' trials following multi-stakeholder collaboration amongst The Michael J. Fox Foundation for Parkinson's Research and the Critical Path Ins
- NephCure Announces First-Ever IgA Nephropathy (IgAN) Awareness Day on September 26, 2024https://reachmd.com/news/nephcure-announces-first-ever-iga-nephropathy-igan-awareness-day-on-september-26-2024/2468134/PHILADELPHIA, Sept. 3, 2024 /PRNewswire/ -- NephCure, a leading nonprofit organization dedicated to finding better treatments and a cure for rare kidney disease, is proud to announce the inaugural IgA Nephropathy (IgAN) Awareness Day on September 26, 2024. The event is specifically dedicated to r
- How Newly Identified Biomarkers Could Reveal Risk Factors for Sudden Infant Death Syndromehttps://reachmd.com/news/how-newly-identified-biomarkers-could-reveal-risk-factors-for-sudden-infant-death-syndrome/2468127/Credit: CC0 Public Domain Researchers at UC San Francisco are getting closer to being able to predict sudden infant death sy
- Travere Therapeutics Announces Full FDA Approval of Filspari (sparsentan), the Only Non-Immunosuppressive Treatment that Significantly Slows Kidney Function Decline in IgA Nephropathyhttps://reachmd.com/news/travere-therapeutics-announces-full-fda-approval-of-filspari-sparsentan-the-only-non-immunosuppressive-treatment-that-significantly-slows-kidney-function-decline-in-iga-nephropathy/2468133/Travere Therapeutics Announces Full FDA Approval of Filspari (sparsentan), the Only Non-Immunosuppressive Treatment that Significantly Slows Kidney Function Decline in IgA Nephropathy SAN DIEGO, Sept. 05, 2024 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc., (N
- Lebrikizumab Shows Significant Improvement in Atopic Dermatitishttps://reachmd.com/news/lebrikizumab-shows-significant-improvement-atopic-dermatitis/2468116/Lebrikizumab monotherapy showed significant improvements in clinical signs, symptoms, and quality of life in patients with moderate-to-severe atopic dermatitis over 16 weeks, according to new research. The analysis of two phase 3 placebo-controlled studies (ADvocate1 and ADvocate2) looked